Your browser is no longer supported. Please, upgrade your browser.
Settings
NEOS [NASD]
Neos Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own1.50% Shs Outstand49.76M Perf Week-14.80%
Market Cap49.33M Forward P/E- EPS next Y-0.06 Insider Trans0.00% Shs Float49.22M Perf Month10.37%
Income-21.90M PEG- EPS next Q0.00 Inst Own20.80% Short Float2.62% Perf Quarter65.84%
Sales57.00M P/S0.87 EPS this Y78.80% Inst Trans-37.32% Short Ratio0.19 Perf Half Y38.76%
Book/sh-0.41 P/B- EPS next Y83.80% ROA-28.50% Target Price1.00 Perf Year-36.10%
Cash/sh0.25 P/C3.88 EPS next 5Y31.70% ROE156.00% 52W Range0.45 - 1.62 Perf YTD55.48%
Dividend- P/FCF- EPS past 5Y28.10% ROI-26.90% 52W High-40.04% Beta1.55
Dividend %- Quick Ratio0.50 Sales past 5Y143.30% Gross Margin56.90% 52W Low115.80% ATR0.13
Employees213 Current Ratio0.70 Sales Q/Q-28.60% Oper. Margin-23.70% RSI (14)51.67 Volatility10.96% 12.37%
OptionableYes Debt/Eq- EPS Q/Q-139.30% Profit Margin-38.40% Rel Volume0.32 Prev Close0.97
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume6.85M Price0.97
Recom2.00 SMA20-0.14% SMA5017.76% SMA20036.37% Volume0 Change0.00%
Aug-09-17Reiterated RBC Capital Mkts Outperform $20 → $12
Aug-01-17Initiated Cantor Fitzgerald Overweight $20
Mar-20-17Downgrade UBS Buy → Neutral $11 → $8
May-17-16Reiterated RBC Capital Mkts Outperform $33 → $29
Feb-19-16Initiated Wells Fargo Outperform
Nov-12-15Reiterated RBC Capital Mkts Outperform $35 → $33
Aug-17-15Initiated RBC Capital Mkts Outperform $35
Aug-17-15Initiated JMP Securities Mkt Outperform $32
Feb-10-21 08:00AM  
08:00AM  
Jan-30-21 07:06PM  
Jan-28-21 02:28PM  
11:04AM  
Jan-06-21 07:58AM  
Jan-04-21 04:01PM  
Dec-28-20 08:15PM  
Dec-24-20 10:49PM  
Dec-19-20 04:11PM  
Dec-16-20 09:20PM  
Dec-12-20 08:58AM  
Dec-11-20 11:41AM  
10:38AM  
Dec-10-20 07:35PM  
07:03PM  
04:52PM  
10:31AM  
09:44AM  
08:00AM  
06:01AM  
Dec-07-20 04:04PM  
Nov-09-20 11:38AM  
07:20AM  
07:00AM  
06:30AM  
Nov-02-20 08:00AM  
Oct-20-20 09:52AM  
Oct-19-20 03:30PM  
Sep-09-20 08:00AM  
Aug-10-20 07:21AM  
07:00AM  
Aug-03-20 08:00AM  
Jul-08-20 06:14PM  
08:22AM  
Jun-16-20 08:00AM  
May-26-20 08:00AM  
May-11-20 04:01PM  
May-04-20 04:05PM  
Apr-09-20 08:00AM  
Mar-30-20 08:00AM  
Mar-26-20 06:46PM  
Mar-17-20 08:25AM  
Mar-13-20 07:47AM  
Mar-06-20 08:00AM  
Feb-26-20 08:00AM  
Jan-13-20 08:00AM  
Jan-06-20 10:57AM  
Dec-17-19 07:47PM  
Nov-16-19 09:39PM  
Nov-08-19 07:00AM  
Nov-01-19 08:00AM  
Oct-28-19 03:46PM  
Sep-25-19 08:00AM  
Aug-29-19 08:00AM  
Aug-16-19 10:57PM  
Aug-08-19 08:35AM  
07:00AM  
Aug-01-19 08:00AM  
Jul-09-19 04:45PM  
Jun-26-19 08:32AM  
Jun-12-19 08:00AM  
May-30-19 08:00AM  
May-24-19 06:56AM  
May-23-19 01:45AM  
May-09-19 08:35AM  
07:29AM  
07:00AM  
May-02-19 08:00AM  
May-01-19 10:32AM  
Mar-22-19 08:48AM  
Mar-20-19 05:42PM  
Mar-18-19 10:48AM  
Mar-14-19 08:01AM  
07:47AM  
07:00AM  
Mar-07-19 08:00AM  
Mar-06-19 08:00AM  
Feb-26-19 08:25AM  
Jan-30-19 08:00AM  
Dec-27-18 09:39AM  
09:37AM  
07:06AM  
Dec-26-18 10:48AM  
08:00AM  
07:30AM  
Nov-30-18 07:30AM  
Nov-27-18 09:00AM  
08:40AM  
Nov-17-18 03:34PM  
Nov-09-18 08:35AM  
07:29AM  
07:00AM  
Nov-06-18 09:21AM  
Nov-05-18 04:03PM  
Nov-02-18 07:30AM  
Oct-24-18 08:00AM  
Oct-23-18 08:00AM  
Oct-16-18 07:35AM  
Sep-26-18 07:30AM  
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.